These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

273 related articles for article (PubMed ID: 23596549)

  • 1. Therapeutic potential of targeting the renin angiotensin system in portal hypertension.
    Herath CB; Grace JA; Angus PW
    World J Gastrointest Pathophysiol; 2013 Feb; 4(1):1-11. PubMed ID: 23596549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cirrhotic portal hypertension: From pathophysiology to novel therapeutics.
    Gunarathne LS; Rajapaksha H; Shackel N; Angus PW; Herath CB
    World J Gastroenterol; 2020 Oct; 26(40):6111-6140. PubMed ID: 33177789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Update on New Aspects of the Renin-Angiotensin System in Hepatic Fibrosis and Portal Hypertension: Implications for Novel Therapeutic Options.
    Rajapaksha IG; Gunarathne LS; Angus PW; Herath CB
    J Clin Med; 2021 Feb; 10(4):. PubMed ID: 33670126
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of the MAS receptor by angiotensin-(1-7) in the renin-angiotensin system mediates mesenteric vasodilatation in cirrhosis.
    Grace JA; Klein S; Herath CB; Granzow M; Schierwagen R; Masing N; Walther T; Sauerbruch T; Burrell LM; Angus PW; Trebicka J
    Gastroenterology; 2013 Oct; 145(4):874-884.e5. PubMed ID: 23796456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blockade of Mas Receptor or Mas-Related G-Protein Coupled Receptor Type D Reduces Portal Pressure in Cirrhotic but Not in Non-cirrhotic Portal Hypertensive Rats.
    Gunarathne LS; Angus PW; Herath CB
    Front Physiol; 2019; 10():1169. PubMed ID: 31607942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension.
    Shim KY; Eom YW; Kim MY; Kang SH; Baik SK
    Korean J Intern Med; 2018 May; 33(3):453-461. PubMed ID: 29462546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complications of cirrhosis. I. Portal hypertension.
    Bosch J; García-Pagán JC
    J Hepatol; 2000; 32(1 Suppl):141-56. PubMed ID: 10728801
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacologic prevention of variceal bleeding and rebleeding.
    Baiges A; Hernández-Gea V; Bosch J
    Hepatol Int; 2018 Feb; 12(Suppl 1):68-80. PubMed ID: 29210030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options.
    Grace JA; Herath CB; Mak KY; Burrell LM; Angus PW
    Clin Sci (Lond); 2012 Aug; 123(4):225-39. PubMed ID: 22548407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Portal hypertension: from pathophysiology to clinical practice.
    Laleman W; Landeghem L; Wilmer A; Fevery J; Nevens F
    Liver Int; 2005 Dec; 25(6):1079-90. PubMed ID: 16343056
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathophysiology and a Rational Basis of Therapy.
    Gracia-Sancho J; Maeso-Díaz R; Bosch J
    Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiology of portal hypertension and its clinical links.
    Seo YS; Shah VH
    J Clin Exp Hepatol; 2011 Sep; 1(2):87-93. PubMed ID: 25755320
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activation of the Alternate Renin-Angiotensin System Correlates with the Clinical Status in Human Cirrhosis and Corrects Post Liver Transplantation.
    Casey S; Schierwagen R; Mak KY; Klein S; Uschner F; Jansen C; Praktiknjo M; Meyer C; Thomas D; Herath C; Jones R; Trebicka J; Angus P
    J Clin Med; 2019 Mar; 8(4):. PubMed ID: 30934723
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel treatment options for portal hypertension.
    Schwabl P; Laleman W
    Gastroenterol Rep (Oxf); 2017 May; 5(2):90-103. PubMed ID: 28533907
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of Oesophageal Varices in Liver Cirrhosis.
    Sauerbruch T; Wong F
    Digestion; 2019; 99(4):261-266. PubMed ID: 30212817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-line drugs inhibiting the renin angiotensin system versus other first-line antihypertensive drug classes for hypertension.
    Xue H; Lu Z; Tang WL; Pang LW; Wang GM; Wong GW; Wright JM
    Cochrane Database Syst Rev; 2015 Jan; 1():CD008170. PubMed ID: 25577154
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Recent advances in promising drugs for primary prevention of gastroesophageal variceal bleeding with cirrhotic portal hypertension.
    Sheng JY; Meng ZF; Li Q; Yang YS
    Hepatobiliary Pancreat Dis Int; 2024 Feb; 23(1):4-13. PubMed ID: 37580228
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver disease and the renin-angiotensin system: recent discoveries and clinical implications.
    Lubel JS; Herath CB; Burrell LM; Angus PW
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1327-38. PubMed ID: 18557800
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Band ligation versus sham or no intervention for primary prophylaxis of oesophageal variceal bleeding in children and adolescents with chronic liver disease or portal vein thrombosis.
    Cifuentes LI; Gattini D; Torres-Robles R; Gana JC
    Cochrane Database Syst Rev; 2021 Jan; 1(1):CD011561. PubMed ID: 33522602
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevention and treatment of variceal haemorrhage in 2017.
    Brunner F; Berzigotti A; Bosch J
    Liver Int; 2017 Jan; 37 Suppl 1():104-115. PubMed ID: 28052623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.